An experimental drug has shown promising results in treating metastatic pancreatic cancer, doubling the median survival rate for patients. This development offers a significant advancement in the fight against one of the most aggressive forms of cancer.
Researchers anticipate this breakthrough could lead to a "dramatic shift" in how pancreatic cancer is managed. The findings provide new hope for patients facing this challenging diagnosis, potentially transforming future treatment protocols.